soul trial oral semaglutide cardiovascular outcomes 2024 nejm results soul trial oral semaglutide cardiovascular outcomes 2024 results Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis Semaglutide and Cardiovascular Outcomes in

Therefore, the advice can vary, she says

If semaglutide really isn't making a difference, they may recommend a different weight loss medication, like tirzepatide (sold under the brand names Mounjaro and Zepbound)

GLP-1RAs show modest SBP reductions (1.85.1 mmHg) and minimal DBP effects (~ 0.5 mmHg), though tirzepatide shows greater efficacy (~ 10.6 mmHg) in select populations

If you're uncertain about the best timing for your specific medication, consult your GP or diabetes specialist nurse for personalised guidance based on the product's SmPC

Cancellations made after your next shipment has been processed will apply to the following billing cycle. If you have any questions or need assistance, please contact our support team at [email protected]